A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
Phase of Trial: Phase II/III
Latest Information Update: 13 May 2011
At a glance
- Drugs Menatetrenone (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 13 May 2011 Results published in the Hepatology.
- 13 May 2011 Primary endpoint 'Disease-free-survival' has not been met, based on results published in Hepatology.
- 23 Oct 2008 Planned patient number (540) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History